{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotonic+solution&page=6",
    "query": {
      "intervention": "Isotonic solution",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1141,
    "total_pages": 115,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotonic+solution&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotonic+solution&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T22:22:52.334Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01325493",
      "title": "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Idiopathic Scoliosis",
        "Spondylolisthesis"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Julia Finkel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 54,
      "start_date": "2010-01",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325493"
    },
    {
      "nct_id": "NCT05210504",
      "title": "Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "L-Lysine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 23,
      "start_date": "2022-03-09",
      "completion_date": "2023-01-27",
      "has_results": true,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05210504"
    },
    {
      "nct_id": "NCT02515175",
      "title": "Evaluating New Formulation of Therapeutic HSV-2 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "Matrix-M2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GEN-003",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 131,
      "start_date": "2015-11",
      "completion_date": "2017-05-25",
      "has_results": false,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02515175"
    },
    {
      "nct_id": "NCT01593072",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Hemorrhagic Fever"
      ],
      "interventions": [
        {
          "name": "AVI-7537",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline Solution (NSS)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01593072"
    },
    {
      "nct_id": "NCT04759339",
      "title": "An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AG-920",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Genomics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2021-02-24",
      "completion_date": "2021-02-25",
      "has_results": false,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04759339"
    },
    {
      "nct_id": "NCT02140762",
      "title": "Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningococcal Disease"
      ],
      "interventions": [
        {
          "name": "MenABCWY",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "MenACWY",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 305,
      "start_date": "2014-05",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2018-09-12",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 8,
      "location_summary": "Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02140762"
    },
    {
      "nct_id": "NCT03302754",
      "title": "Precision Dosing of Alemtuzumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "6 Weeks to 30 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-10-05",
      "completion_date": "2019-03-10",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03302754"
    },
    {
      "nct_id": "NCT01270854",
      "title": "Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Wounds and Injuries",
        "Multiple Trauma",
        "Disorder of Fluid Balance"
      ],
      "interventions": [
        {
          "name": "Plasmalyte A",
          "type": "OTHER"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2011-02",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01270854"
    },
    {
      "nct_id": "NCT02930941",
      "title": "Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epistaxis"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2016-02",
      "completion_date": "2020-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02930941"
    },
    {
      "nct_id": "NCT01575054",
      "title": "BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscle Spasticity"
      ],
      "interventions": [
        {
          "name": "botulinum toxin Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 468,
      "start_date": "2012-05",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-11-11T22:22:52.334Z",
      "location_count": 2,
      "location_summary": "Downey, California • Daytona Beach, Florida",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575054"
    }
  ]
}